Browse > Article

The Analysis of Interrelationship between Homocysteine and Methylenetetrahydrofolate Reductase Mutation in Patients with Recurrent Spontaneous Abortion  

Nam, Yoon-Sung (Department of Obstetrics and Gynecology, College of Medicine, Pocheon CHA University)
Cha, Kwang-Yul (Department of Obstetrics and Gynecology, College of Medicine, Pocheon CHA University)
Kim, Nam-Keun (Institute for Clinical Research, College of Medicine, Pocheon CHA University)
Kang, Myung-Seo (Institute for Clinical Research, College of Medicine, Pocheon CHA University)
Kim, Se-Hyun (Institute for Clinical Research, College of Medicine, Pocheon CHA University)
Oh, Do-Yeon (Institute for Clinical Research, College of Medicine, Pocheon CHA University)
Publication Information
Clinical and Experimental Reproductive Medicine / v.29, no.3, 2002 , pp. 187-193 More about this Journal
Abstract
Objective : To analyze the interrelationship between homocysteine and methylenetetrahydrofolate reductase (MTHFR) mutation in patients with recurrent spontaneous abortion. Material and Method: Homocysteine and MTHFR mutation were tested by fluorescent polarizing immunoassay and PCR-RFLP method, respectively. Results: In patients with homocysteine level less than 5 ?mol/L, there was no case of normal group but there were four cases of heterozygosity and one case of homozygosity. In patients with homocysteine level 5$\sim$10 ? mol/L, the number of normal, heterozygosity and homozygosity group were eleven, eighteen and eight, respectively. In patients with homocysteine level $10{\sim}15$ ? mol/L, the number of normal, heterozygosity and homozygosity group were four, one and one, respectively. In patients with homocysteine level more than 15 ? mol/L, there was no case of normal and heterozygosity group but there were two cases of homozygosity. Conclusions: Hyperhomocysteinemia due to MTHFR mutation is a cause of recurrent spontaneous abortion. And there was a significant relationship between homocysteine and MTHFR mutation.
Keywords
Recurrent spontaneous abortion; Homocysteine; MTHFR mutation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet, and cardiovascular disease. A healthcare statement for healthcare professionals from the nutrition committee. American Heart Association. Circulation 1999; 99: 178-82
2 Nordstrom M, Kellstrom T. Age dependency of cystathionine ?-synthase activity in human fibroblasts in homocysteinemia and atherosclerotic vascular disease. Atherosclerosis 1992; 94: 213-21   DOI
3 Blom HJ, Kleinveld HA, Boers GHJ, Demacker PNM, Hak-Lemmers HLM, Poele-Pothoff MTWB, et al. Lipid peroxidation and susceptibility of low density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-54   DOI   ScienceOn
4 Franken PDG, Boers GHJ, Blom HJ, Cruysberg JRM, Trijbels FJM, Hamel BCJ. Prevalence of familial mild hyperhomocysteinemia. Atherosclerosis 1996; 125: 71-80   DOI   ScienceOn
5 Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for at herosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-6   DOI   ScienceOn
6 Zighetti ML, Cattaneo M, Tsai MY. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep vein thrombosis in patients with mutant factor V (factor V: $Q^{506}$). Thromb Haemost 1997; Supplement: 570
7 den Heijer M, Koster T, Blom HJ. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334: 759-62   DOI   ScienceOn
8 Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1764-79   PUBMED
9 Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine / homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy and enzymology. Arterioscler Thromb 1993; 13: 1253-60   DOI   PUBMED
10 Ubbink J, Vermaak W, Van der Merwe A, Becker P, Delport R, Potgeiter H. Vitamin requirements for the treatment of hyperhomocysteinaemia in humans. J Nutr 1994; 124: 1927-33   DOI   PUBMED
11 Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Rad Biol Med 1993; 14: 683-93   DOI   ScienceOn
12 Ubbink JB. Homocysteine - an atherogenic and a thrombogenic factor? Nutr Rev 1995; 53: 323-5
13 Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary disease. Am J Hum Genet 1991; 48: 536-45   PUBMED
14 Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Kakobs C, et al. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-8   DOI   ScienceOn
15 Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost 1997; 78: 527-31
16 Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27   DOI   ScienceOn
17 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic and intakes. JAMA 1995; 274: 1049-57   DOI
18 Robinson K, Mayer EL, Miller DP, Green R, Van-Lente F, Gupta A, et al. Hyperhomocysteinaemia and low pyridoxal phosphate. Circulation 1995; 92: 2825-30   DOI   PUBMED   ScienceOn
19 Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9   DOI   ScienceOn
20 Kang SS, Wong PW, Manilow MR. Homocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279-98   DOI   ScienceOn
21 Carey MC, Donovan DE, FutzGerald O, McAuley FD. Homocystinuria: A clinical and pathological study of nine subjects in six families. Am J Med 1968; 48: 7-25
22 D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11   PUBMED
23 Nelen WLDM, Blom HJ, Steegers EAP, Heijer MD, Eskes TKAB. Hyperhomocysteinemia and recurrent early pregnancy loss: meta-analysis. Fertil Steril 2000; 74: 1196-9   DOI   ScienceOn
24 Brenner B, Sarig G, Weinner Z, Younis Y, Blumfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9   PUBMED
25 Nelen WLDM, Heil SG, Steegers EAP, Eskes TKAB. Recurrent early pregnancy loss and genetic- related disturbances in folate and homocysteine metabolism. Br J Hosp Med 1997; 58: 511-3
26 Malinow R, Javier F, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation 1993; 87: 1107-13   DOI   ScienceOn
27 McCully KS. Chemical pathology of homocysteine. Ann Clin Lab Sci 1994; 24: 27-59   PUBMED
28 Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, et al. Association between plasma homocysteine concentration and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286-91   DOI   ScienceOn
29 Mandel H, Brenner B, Berant M. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996; 334: 763-8   DOI   ScienceOn
30 Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in U.S. physicians. Circulation 1996; 94: 2410-6   DOI   ScienceOn
31 Nelson WLDM, Steegers EAP, Eskes TKAB, Blom JH. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997; 350: 861
32 de Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg BME, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynecol 1997; 104: 1248-54   DOI
33 Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, et al. Mutated methy lenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1   DOI   ScienceOn
34 Guttormsen A, Nesthus I, Uleland P, Nygard O, Schneede J, Vollset SE, et al. Determinants and vitamin resp onsiveness of intermediate hyperhomocysteinemia (>40 ? mol/L). J Clin Invest 1996; 68: 2174-83
35 Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocysteine concentrations by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338: 1009-15   DOI   ScienceOn
36 Girling J, de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998; 10: 135-44   DOI
37 Tucker KL, Mahnken B, Wilson WF, Jacques P, Selhub J. Folic acid fortification of the food supply: Potential benefits and risk for the elderly population. JAMA 1996; 276: 1879-85   DOI
38 Welch GN, Upchurch GR, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract 1997; 70: 87-92
39 Ubbink JB. Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr Rev 1994; 52: 383-93   DOI   PUBMED   ScienceOn
40 Masser P, Taylor LM, Porter JM. Importance of elevated homocysteine concentrations as a risk factor for atherosclerosis. Ann Thorac Surg 1994; 58: 1240-6   DOI   PUBMED   ScienceOn